The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, Myovant, oral, relugolix | 2 Comments »
A poster presentation given the other day at the annual meeting of the Canadian Urological Association addressed the relative cardiovascular risks of LHRH agonist and antagonist therapies. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardivascular, complication, LHRH, risk | Leave a comment »
Since 2007 a randomized clinical trial in the UK (the so-called PATCH trial) has been comparing the effectiveness and safety of transdermal estradiol patches to implants of an LHRH receptor agonist (goserelin acetate) in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen, deprivation, estradiol, LHRH, outcome, PATCH | Leave a comment »
A new paper from a panel of experts in the UK has suggested that the use of LHRH antagonists (e.g., degarelix) may be more appropriate than the use of LHRH agonists (e.g., leuprolide acetate of goserelin acetate) in some prostate cancer patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardiovascular, LHRH, risk | 3 Comments »
Today’s news contained items that run the spectrum from the clinical value of tomatoes and lycopene via the cardiovascular side effects of LHRH agonists and antagonists to the question of whether proton beam radiation therapy is really cost-effective. So here are the “news shorts” for the day: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: agonist, antagonist, cost-effectiveness, LHRH, lycopene, proton beam, PSA density, side effect, testosterone, tomato | 3 Comments »
One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, benefit, Degarelix, LHRH, outcome, survival | 1 Comment »
